Health
Immunotherapy combination shrinks rare angiosarcoma tumors in 25% of patients – News-Medical.Net
Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute’s Division of Cancer Diagnosis and Treatment,…
Reviewed by Emily Henderson, B.Sc.Nov 15 2020
Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute’s (NCI) Division of Cancer Diagnosis and Treatment (DCTD), part of the National Institutes of Health, have shown that the immunotherapy combination of ipilimumab and nivolumab shrinks rare angiosarcoma tumors in 25 percent of all patients, with some having an even stronger response to the drug combination.
Results of the SWOG study, led…
-
Noosa News18 hours agoDaly Cherry-Evans set to be dropped as Maroons captain
-
General24 hours agoBusinesses and consumers caught between opposing forces
-
Noosa News18 hours agoThe Story Bridge should serve as a warning – and an opportunity
-
General17 hours agoHundreds gather in Gin Gin at vigil for allegedly murdered teen Pheobe Bishop